Efficacy of cannabinoids in pharmacoresistant epilepsy: A narrative review of the literature

Alexandra Ferreiros; Elkin Beltrán-Carrascal; Paula Restrepo; Camila Pantoja; Camilo Castañeda-Cardona; Pieralessandro Lasalvia; Laura Van Der Werf; Daniel Nariño; Diego Rosselli

doi:10.17533/udea.iatreia.42

Efficacy of cannabinoids in pharmacoresistant epilepsy: A narrative review of the literature

Título traducido de la contribución: Eficacia de los canabinoides en epilepsia refractaria: Una revisión narrativa de la literatura

Alexandra Ferreiros, Elkin Beltrán-Carrascal, Paula Restrepo, Camila Pantoja, Camilo Castañeda-Cardona, Pieralessandro Lasalvia, Laura Van Der Werf, Daniel Nariño, Diego Rosselli

Producción: Contribución a una revista › Artículo › revisión exhaustiva

1 Cita (Scopus)

Resumen

Epilepsy is a common neurological disorder that affects approximately 1% of the world’s pop7u-lation. About one third of those patients suffer from treatment-resistant epilepsy (TRE8), defined as failure to stop seizures despite adequate trials of at least two medications at therapeutic dosa-ges. There has been a growing interest in the development of novel antiepileptic drugs with different mechanisms of action. This narrative review, based on 42 references retrieved from Scopus and Medline, discusses the scientific data from human and animal studies regarding the efficacy of cannabis-based treatment for epilepsy. Benefits have been described in pre-clinical and clinical studies in children, but ongoing research will clarify the real role of cannabinoids in TRE.

Título traducido de la contribución	Eficacia de los canabinoides en epilepsia refractaria: Una revisión narrativa de la literatura
Idioma original	Inglés
Páginas (desde-hasta)	167-176
Número de páginas	10
Publicación	Iatreia
Volumen	33
N.º	2
DOI	https://doi.org/10.17533/udea.iatreia.42
Estado	Publicada - 01 abr. 2020

Acceder al documento

10.17533/udea.iatreia.42

Otros archivos y enlaces

Enlace a la publicación en Scopus

Citar esto

@article{02a6ac59b4344eb8af4cbff74a661bfe,

title = "Efficacy of cannabinoids in pharmacoresistant epilepsy: A narrative review of the literature",

abstract = "Epilepsy is a common neurological disorder that affects approximately 1% of the world{\textquoteright}s pop7u-lation. About one third of those patients suffer from treatment-resistant epilepsy (TRE8), defined as failure to stop seizures despite adequate trials of at least two medications at therapeutic dosa-ges. There has been a growing interest in the development of novel antiepileptic drugs with different mechanisms of action. This narrative review, based on 42 references retrieved from Scopus and Medline, discusses the scientific data from human and animal studies regarding the efficacy of cannabis-based treatment for epilepsy. Benefits have been described in pre-clinical and clinical studies in children, but ongoing research will clarify the real role of cannabinoids in TRE.",

keywords = "Cannabis, Drug Resistant Epilepsy, Review",

author = "Alexandra Ferreiros and Elkin Beltr{\'a}n-Carrascal and Paula Restrepo and Camila Pantoja and Camilo Casta{\~n}eda-Cardona and Pieralessandro Lasalvia and {Van Der Werf}, Laura and Daniel Nari{\~n}o and Diego Rosselli",

year = "2020",

month = apr,

day = "1",

doi = "10.17533/udea.iatreia.42",

language = "English",

volume = "33",

pages = "167--176",

journal = "Iatreia",

issn = "0121-0793",

publisher = "Universidad de Antioquia",

number = "2",

}

TY - JOUR

T1 - Efficacy of cannabinoids in pharmacoresistant epilepsy

T2 - A narrative review of the literature

AU - Ferreiros, Alexandra

AU - Beltrán-Carrascal, Elkin

AU - Restrepo, Paula

AU - Pantoja, Camila

AU - Castañeda-Cardona, Camilo

AU - Lasalvia, Pieralessandro

AU - Van Der Werf, Laura

AU - Nariño, Daniel

AU - Rosselli, Diego

PY - 2020/4/1

Y1 - 2020/4/1

N2 - Epilepsy is a common neurological disorder that affects approximately 1% of the world’s pop7u-lation. About one third of those patients suffer from treatment-resistant epilepsy (TRE8), defined as failure to stop seizures despite adequate trials of at least two medications at therapeutic dosa-ges. There has been a growing interest in the development of novel antiepileptic drugs with different mechanisms of action. This narrative review, based on 42 references retrieved from Scopus and Medline, discusses the scientific data from human and animal studies regarding the efficacy of cannabis-based treatment for epilepsy. Benefits have been described in pre-clinical and clinical studies in children, but ongoing research will clarify the real role of cannabinoids in TRE.

AB - Epilepsy is a common neurological disorder that affects approximately 1% of the world’s pop7u-lation. About one third of those patients suffer from treatment-resistant epilepsy (TRE8), defined as failure to stop seizures despite adequate trials of at least two medications at therapeutic dosa-ges. There has been a growing interest in the development of novel antiepileptic drugs with different mechanisms of action. This narrative review, based on 42 references retrieved from Scopus and Medline, discusses the scientific data from human and animal studies regarding the efficacy of cannabis-based treatment for epilepsy. Benefits have been described in pre-clinical and clinical studies in children, but ongoing research will clarify the real role of cannabinoids in TRE.

KW - Cannabis

KW - Drug Resistant Epilepsy

KW - Review

UR - http://www.scopus.com/inward/record.url?scp=85083858022&partnerID=8YFLogxK

U2 - 10.17533/udea.iatreia.42

DO - 10.17533/udea.iatreia.42

M3 - Article

AN - SCOPUS:85083858022

SN - 0121-0793

VL - 33

SP - 167

EP - 176

JO - Iatreia

JF - Iatreia

IS - 2

ER -

Efficacy of cannabinoids in pharmacoresistant epilepsy: A narrative review of the literature

Resumen

Acceder al documento

Otros archivos y enlaces

Huella

Citar esto